Abstract
Twelve children (10 girls, 2 boys)with precocious puberty were treated with Nafarelin, an intranasal GnRH analog, for 6 months. Seven patients (mean age of 6.8 yrs) received 800 mcg and five patients (mean age of 7.8 yrs) received 1600 mcg daily at night. Standard LHRH tests were performed and secondary sex characteristics were assessed at 0, 3, and 6 months of therapy. Results are reported as mean ± SE.
At 3 months of therapy the higher dose of nafarelin produced a significantly greater (p<.05) suppression of peak LH levels during the LHRH test. These differences were not significant by six months of therapy. Regression of breast development and reduction in pubic hair appeared to occur earlier in the children treated with the higher dose. These data suggest that the higher dose of Nafarelin may initiate a more rapid suppression of serum LH response and normalization of pubertl development. Follow-up studies are essential to determine if a more rapid decrease in LH will have a long-term impact on growth dynamics in children with precocious puberty.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brzyski, R., French, C. & Comite, F. DOSE-RELATED SUPPRESSION OF LH RESPONSE TO LHRH AND CLINICAL PARAMETERS BY NAFARELIN, AN INTRANASAL GnRH ANALOG. Pediatr Res 21 (Suppl 4), 244 (1987). https://doi.org/10.1203/00006450-198704010-00464
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-00464